ClotProtect Therapeutics

ClotProtect Therapeutics is a University of Leeds spin-out developing a first-in-class small molecule anti-fibrinolytic to address acute bleeding following trauma and surgery.

The company's approach directly inhibits the enzyme responsible for blood clot breakdown, aiming to offer greater efficacy than current standard-of-care treatments.

Currently in preclinical development, ClotProtect is working towards identifying a clinical drug candidate, targeting a treatment area where bleeding remains a leading cause of preventable death.